DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Adebrelimab
Radiation: Radiation Therapy
Drug: etoposide, carboplatin(EC)

First Posted Date: 2024-02-01

Last Posted Date: 2024-02-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 48

Registration Number: NCT06236997

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Tongji Hospital, Tongji Medical College，Huazhong University of Science and Technology, Wuhan, Hubei, China

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2

Recruiting

Conditions: Lung Cancer, Nonsmall Cell
Esophageal Carcinoma

Interventions: Drug: Thalidomide 200mg
Drug: Camrelizumab
Drug: Thalidomide 100mg
Drug: Thalidomide 50mg
Drug: Chemotherapy

First Posted Date: 2024-01-30

Last Posted Date: 2024-03-29

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 132

Registration Number: NCT06231680

Locations: 🇨🇳
Ying Liu, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: RC48 combined with Sintilimab and XELOX

First Posted Date: 2024-01-26

Last Posted Date: 2024-01-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 27

Registration Number: NCT06227325

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Phase 2

Recruiting

Conditions: HR Low/HER2 Negative
Treatment
Advanced Breast Cancer

First Posted Date: 2023-12-19

Last Posted Date: 2024-08-20

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 240

Registration Number: NCT06176534

Locations: 🇨🇳
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Not Applicable

Recruiting

Conditions: Non-hodgkin Lymphoma,B Cell

Interventions: Biological: CART-19 and 20 cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-12-07

Last Posted Date: 2023-12-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT06160362

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Go-CHOP as the Frontline Therapy for PTCL

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: CHOP Regimen

First Posted Date: 2023-07-27

Last Posted Date: 2023-09-01

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT05963347

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain

Recruiting

Conditions: Cancer Pain
Real-world Study
Oxycodone

First Posted Date: 2023-07-27

Last Posted Date: 2023-07-27

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 916

Registration Number: NCT05962294

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Early Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: RD13-02 cell infusion

First Posted Date: 2023-06-28

Last Posted Date: 2024-11-22

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 6

Registration Number: NCT05923541

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2

Recruiting

Conditions: Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib
Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab

First Posted Date: 2023-06-26

Last Posted Date: 2025-03-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 610

Registration Number: NCT05918328

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Phase 2

Recruiting

Conditions: HER2 Low Breast Carcinoma

Interventions: Drug: SHR-A1811 for injection

First Posted Date: 2023-06-22

Last Posted Date: 2024-11-04

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 66

Registration Number: NCT05911958

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy